Skip to main content

ELV Elevance Health Inc.

Healthcare

413.60 -6.46 -1.54% Close 11/2
Since 2024-12-02 +6.3%
Open
421.34
High
424.11
Low
406.90
Prev close
420.07
Volume
2.1M
Amplitude
4.10%
P/E
17.9
P/B
2.0
Revenue YoY (TTM)
+3.6%
52W 274.84 450.69

Is Elevance Health Inc. a buy? Fundamentals and valuation first

As of 2026-10-30

Valuation: Fair, Momentum: Strong, Risk / liquidity: Strong.

Valuation Fair Free-cash-flow yield is Good, but Price / book is Pricey.
TTM P/E 17.91 48th percentile Fair
Price / book 2.03 60th percentile Pricey
Free-cash-flow yield (%) 7.18 74th percentile Good
US Stock Backtest in Python: Price-to-Book Ratio StrategyQuality Factor Investing: A US Quality Value Backtest
Quality Neutral ROE, TTM is Good, but Operating margin, TTM is Average.
ROE, TTM (%) 11.5 69th percentile Good
Operating margin, TTM (%) 3.69 43th percentile Average
FCF margin, TTM (%) 3.23 47th percentile Average
Quality Factor Investing: A US Quality Value Backtest
Growth Neutral Diluted EPS growth, TTM YoY is Good, but Revenue growth, TTM YoY is Average.
Revenue growth, TTM YoY (%) 3.6 44th percentile Average
Diluted EPS growth, TTM YoY (%) -4.13 53th percentile Good
Momentum Strong 60-day return is Top; 240-day return is Good.
60-day return (%) 7.77 83th percentile Top
240-day return (%) 31.47 79th percentile Good
Momentum Trading Strategy: A 12-1 Momentum Backtest
Risk / liquidity Strong 20-day dollar volume is Top; 60-day annualized volatility is Good.
20-day dollar volume 569,264,484 98th percentile Top
60-day annualized volatility (%) 24.84 28th percentile Good
Factor Investing Explained: 10 Classic Factors in US Stocks

Elevance Health Inc. (ELV) today

1 quant signals active · As of 2026-10-30

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

FinLab Studio

From Elevance Health Inc. to every stock like it

AI finds several complementary traits of Elevance Health Inc. across different dimensions, combines them into a multifactor strategy, and backtests it against the market.

Screen stocks like Elevance Health Inc.

Elevance Health Inc. (ELV) peers and tracking

Watchlist

This page refreshes daily after the close. Add Elevance Health Inc. to your watchlist to track signal changes on your next visit.

Elevance Health Inc. (ELV) quant signal backtests

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

EPS surprise beat

Active · now 48.41%

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

PEAD: Post-Earnings Announcement Drift Backtest
19 historical occurrences (since 2015-04-29)

Average forward return after EPS surprise beat

20-day: Win 53.3%, Sample 15, Median +0.59%, Excess -1.04%, Beat mkt rate 26.7%

60-day: Win 80%, Sample 15, Median +3.14%, Excess +0.4%, Beat mkt rate 60%

120-day: Win 78.6%, Sample 14, Median +9.51%, Excess +2.77%, Beat mkt rate 57.1%

120 days after: historical avg +8.51%

20-day +0.31%
60-day +4.41%
120-day +8.51%
20-day
60-day
120-day
Win
53.3%
80%
78.6%
Sample
15
15
14
Median
+0.59%
+3.14%
+9.51%
Excess
-1.04%
+0.4%
+2.77%
Beat mkt rate
26.7%
60%
57.1%

Over 14 occurrences, 120-day forward avg gained 8.51%, beat the market by 2.77 pts; win rate 78.6%.

Valuation regime and forward returns

Daily TTM P/E is converted into an expanding own-history percentile, then grouped into five valuation regimes. Forward returns use adjusted prices over the next 240 trading days.

PE percentile bandSample days240-day avg returnMedianWin rateAvg excess (vs index)
0-20 386+22% +29.7% 73.8% -2.8%
20-40 153+6.8% +19.1% 59.5% -16.7%
40-60 You are here198+10.3% +13.8% 72.7% -12.6%
60-80 377-4.2% -3.3% 34.7% -13.7%
80-100 325+8.2% +17.2% 58.2% +6.8%

Quarterly EPS is aligned by SEC filing date before it is forward-filled to daily prices. The expanding percentile uses only information available up to each day.

Current TTM P/E is about 17.91, placing it in the 52.6 own-history percentile, inside the 40-60 bucket.

More history: Valuation × momentum analogs, Market-wide momentum baseline, Signals not active now

Valuation × momentum analogs

Each historical day is grouped by own-history P/E tercile and 60-day momentum direction, then tested for the next 120-trading-day adjusted return.

Valuation
Momentum
Cheap (own-history bottom third)
Middle
Expensive (own-history top third)
60-day momentum up
+8.5%
Win rate 73.2% Excess -5.1%
254d
Now
+7.3%
Win rate 78.3% Excess -3.8%
184d
+0.9%
Win rate 62% Excess -2.2%
482d
60-day momentum down
+7.7%
Win rate 64.7% Excess -2%
343d
+1.9%
Win rate 60.1% Excess -7%
173d
+9.7%
Win rate 65% Excess +7.3%
123d

Currently in “Middle × 60-day momentum up”: across 184 historical days, 120-day forward avg gained 7.3%, win rate 78.3%, lagged the market by 3.8%.

Days = trading days in this bucket; returns use adjusted prices, ex-costs. 60-day momentum: direction of this stock's price over the past 60 trading days.

Market-wide momentum baseline

Across 99,493 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.42%, a 58.4% positive-return rate, and +3.08 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

28 times historically; 60-day forward avg +3.63%, win rate 74.1%, beating the market by +0.98 pts on average.

Top-quintile 6-month momentum

Pending

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

Momentum Trading Strategy: A 12-1 Momentum Backtest

16 times historically; 60-day forward avg +3.23%, win rate 71.4%, beating the market by +3.14 pts on average.

Filed revenue acceleration

Pending

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

9 times historically; 60-day forward avg +3.69%, win rate 66.7%, beating the market by +1.82 pts on average.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.